Novo Nordisk (NASDAQ Copenhagen: NOVO-B) inflicted much pain—and much-needed pain—on the company when president and CEO Maziar (Mike) Doustdar announced plans to lay off about 9,000 of its 78,400 employees, a spot check of analyst comments by StockWatch found this past week.
https://www.genengnews.com/gen-edge/stockwatch-analysts-see-pain-and-necessity-in-novo-nordisks-9000-layoffs/